

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

**CONVEYING PARTY DATA**

Name	Execution Date
Novo Nordisk A/S	09/08/2005
Dr. Reddy's Research Foundation	02/10/2006

**RECEIVING PARTY DATA**

Name:	Dr. Reddy's Laboratories Limited
Street Address:	7-1-27 Ameerpet
City:	Hyderabad
State/Country:	INDIA
Postal Code:	500 016

Name:	Dr. Reddy's Laboratories, Inc.
Street Address:	200 Somerset Corporate Boulevard
Internal Address:	7th Floor
City:	Bridgewater
State/Country:	NEW JERSEY
Postal Code:	08807

**PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	11079161

**CORRESPONDENCE DATA**

Fax Number: (908)203-6515  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
 Phone: 908-203-4953  
 Email: janisiewski@drreddys.com  
 Correspondent Name: Joan Anisiewski  
 Address Line 1: 200 Somerset Corporate Boulevard  
 Address Line 2: 7th Floor

CH \$40.00 11079161

Address Line 4: Bridgewater, NEW JERSEY 08807

ATTORNEY DOCKET NUMBER:

DRF 3.04-055

NAME OF SUBMITTER:

Joan Anisiewski

Total Attachments: 2

source=BULK 3.04-055 Assignment#page1.tif

source=BULK 3.04-055 Assignment#page2.tif

## ASSIGNMENT

WHEREAS:

**NOVO NORDISK A/S**, a corporation organized under the laws of Denmark, located at Novo Allé, DK-2880 Bagsvaerd, Denmark, and **DR. REDDY'S RESEARCH FOUNDATION**, a corporation organized under the laws of India, located at 7-1-27, Ameerpet, Hyderabad 500 016, India, (hereinafter **ASSIGNORS**), are owners of rights by virtue of previous assignment recorded February 20, 2001, in Reel/Frame 011557/0589. Corrective Assignment recorded January 16, 2002, in Reel/Frame 012487/0186, in discoveries and/or inventions entitled:

**Crystalline R-guanidines, Arginine or (L)-Arginine (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate**

for which a patent application has been filed in the United States on April 17, 2000, as Application No. 09/550,843 (now abandoned), and a continuing application filed in the United States on April 17, 2000, as Application No. 09/551,228 (now abandoned), and a continuing application filed in the United States on July 30, 2002, as Application No. 10/217,593 (now abandoned), and a continuing application filed in the United States on July 30, 2002, as Application No. 10/209,567 (now abandoned), and a continuing application filed in the United States on March 14, 2005, as Application No. 11/079,161.

WHEREAS:

**DR. REDDY'S LABORATORIES LIMITED.**, a corporation organized under the laws of India, located at 7-1-27, Ameerpet, Hyderabad 500 016, Andhra Pradesh, India, and

**DR. REDDY'S LABORATORIES, INC.**, a corporation organized under the laws of New Jersey, located at 200 Somerset Corporate Boulevard, Seventh Floor, Bridgewater, NJ U.S.A. 08807, (hereinafter **ASSIGNEES**).

are desirous of acquiring from **ASSIGNORS**, **ASSIGNORS'** entire interest in, to and under said inventions and/or discoveries and in, to and under any patent or similar legal protection to be obtained therefor in all countries.

NOW, THEREFORE, for good and valuable consideration provided by **ASSIGNEES** to **ASSIGNORS**, the receipt of which is hereby acknowledged, **ASSIGNORS** hereby sell, assign and transfer to **ASSIGNEES**, its successors, legal representatives, or assigns, **ASSIGNORS'** full and exclusive rights, titles and interests to said discoveries and/or inventions in all countries, and to any patents or similar legal protections to be obtained for said inventions and/or discoveries by said patent application(s) or any continuations, continuations-in-part, divisions, renewals,


extensions, substitutions, replacements, or reissues thereof, and every priority right that is or may be predicated upon or arise from any such applications or patents including all rights in or arising from patent applications to which said applications claim priority, or any legal equivalent of any thereof in any country for the full term or terms for which the same may be granted.

SAID ASSIGNORS hereby further covenant and agree that the ASSIGNEES, its successors, legal representatives, and assigns, may make additional patent applications on said discoveries and/or inventions in any country and claim the benefits of the International Convention as deemed fit by ASSIGNEES.


SAID ASSIGNORS further hereby authorize any official of any country or countries whose duty it is to issue any patent on applications as aforesaid, (including but not limited to extensions thereof, renewals thereof, etc.), to issue any such patent or related rights for said discoveries and/or inventions to the ASSIGNEES, as assignees of the entirety of ASSIGNORS' right, title and interest in, to and under the same, for the sole use and behalf of the ASSIGNEES, its successors, legal representatives and assigns.

SAID ASSIGNORS hereby further covenant that ASSIGNORS have full right to convey the entire right, title, and interest herein sold, assigned, transferred, and set over.


This ASSIGNMENT shall be binding upon ASSIGNORS' heirs, executors, administrators, successors, and/or assigns.

Date: 9 October 2005 By:   
Jørgen Brønner  
Chief Financial Officer  
Novo Nordisk A/S

*RBK*

Date: 1 September 2005 By:   
Lars Almbom Jørgensen  
Executive Vice President  
Global Regulatory and Business D.

*AK*

Date: 10th February 2006 By:   
Dr. A. VENKATESWARLU  
Dr. Reddy's Research Foundation  
7-1-27, Ameerpet  
HYDERABAD-500 016. (A.P.)  
INDIA.

Date: \_\_\_\_\_ By: \_\_\_\_\_

.....